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THE USE OF NET BENEFIT IN MODELING NON-PROPORTIONAL HAZARDS 
Background: The hazard ratio (HR), representing the quantified estimate of treatment 
effect in survival analysis, measures the instantaneous relative difference of failure risk 
between two groups. The HR is typically assumed to be independent of time; however, this 
assumption is usually violated in practice. If the proportionality assumption holds, HR can 
be validly with the popular Cox proportional hazards model. When not proportional, the 
Wilcoxon-Gehan has been proposed to test the hypothesis of no difference. These have 
been recently generalized to evaluate differences in survival time for more than zero 
survival differences (the “net survival benefit”).  
Method: In this thesis, an attempt is made to illustrate the properties of generalized 
Wilcoxon Gehan tests as proposed by Buyse (2009). We use the concept of net survival 
benefit to re-analyze the trial by the Gastrointestinal Tumor Study Group (1982) by 
comparing chemotherapy versus combined chemotherapy and radiation in the treatment of 
locally unresectable gastric cancer. Survival times in days, for the 45 patients were 
recorded in each treatment arm. In that trial, a delayed treatment effect was observed, thus 
the HR is non-proportional. To provide a flexible assessment of the treatment effect, the 
net survival benefit was computed using datasets simulated under typical scenarios of 
proportional hazards, such as delayed treatment effect. 
Results: The generalized Wilcoxon statistic U, favored not adding radiation to 
chemotherapy, but only for survival up to 12 months. At Δ=0, U (0) = 491.  In the simulated 
data sets, the confidence interval under the null hypothesis U (0) is (-152, 388). The test 
statistic 491 is outside this interval indicating radiation treatment might be beneficial. At 
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𝑈(12) = 219, it is inside the confidence interval of no treatment effect (-154,268) indicating 
the benefit of Chemo only is gone after 12 months.    
Conclusions: The net survival benefit measured via Buyse’s generalized Wilcoxon 
statistic is a measure of treatment effect that is meaningful whether or not hazards are 
proportional. The associated statistical test is more powerful than the standard log-rank test 
when a delayed treatment effect is anticipated. 
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Chapter One: Background 
 
Survival analysis is part of fundamental statistical methods useful for modelling 
time to event data such as death, heart attack, device failure, etc. This type of analysis is 
also useful in many aspects of legal proceedings including apportioning cost of future 
medical care, estimating years of life lost, evaluating product reliability, assessing drug 
safety, measuring viability of medical therapies and devices, assessing actuarial loss, etc. 
This branch of empirical science entails gathering and analysing data on time until a failure 
event (e.g., death). Survival analysis includes a variety of specific types of data analysis 
including “life table analysis,” “time to failure” methods, and “time to death” analysis 
(Tolley et al., 2016). 
There are several components associated with survival analysis. They are based on 
the usual probability density function and the cumulative density function. Mathematically, 
we define 𝑓(𝑡) as the probability that an event occurred at time t, its cumulative density 
function denoted as  𝐹(𝑡) = 𝑃(𝑇 ≤ 𝑡); implying the probability that an event occurred up 
to time t. The survival function denoted as 𝑆(𝑡), is the probability that the event occurred 
at time beyond t and is given by (Latouche, 2019); 
𝑆(𝑡) = 1 − 𝐹(𝑡) = 1 − 𝑃(𝑇 ≤ 𝑡). 
The hazard function ℎ(𝑡) is defined as the probability that the failure event occurred 
between t and t+Δt conditional that the unit of interest has survived up to t, and it is defined 
mathematically as follows (Latouche, 2019): 
ℎ(𝑡) =
𝑓(𝑡)





The cumulative hazard function 𝐻(𝑡), measures the accumulated hazard up to time t, and 
it is defined as (Latouche, 2019); 
𝐻(𝑡) = 2 ℎ(𝑥)𝑑𝑥 = 2
𝑓(𝑥)











The hazard ratio (HR) (Sedgwick, Hazards and hazard ratios, 2012; Austin, 2007; 
Blagoev, Wilkerson, & Fojo, 2012), which represents the quantified estimate of the 
treatment effect in survival analysis, measures the relative difference of instantaneous risk 
between two groups. Generally, the hazard ratio is a function of time, but is often assumed 
to be proportional over time (and thus constant or independent of time). If the 
proportionality assumption holds, the hazard ratio can be estimated using the popular Cox 
proportional hazards model. Survival curves can be compared directly by the method of 
Kaplan and Meier (Buyse, 2010), while the groups’ survival distributions are compared by 
the log-rank test (Sato & Berry, 1991) or other Kaplan-Meier-based tests (Yavuz, Lambert, 













Chapter Two: Methods 
A number of statistical tests have been considered to compare the survival 
distributions between two groups. We focus in this thesis on non-parametric tests. 
 
The log-rank test 
The log-rank test is most powerful under the assumption of proportional hazards. 
When the proportional hazards assumption is not met, the computed hazard ratio does not 
reliably reflect the treatment benefit, because the true hazard ratio is changing over time 
(Sato & Berry, 1991). Moreover, the standard log-rank test that is optimal under 
proportional hazards, may lack statistical power to compare two treatment groups when 
treatment effects are delayed, in which case a global interpretation of the hazard ratio 
comes into question (Conrad, Furner, & Qian, 1999; Sedgwick, 2011). Weighted log-rank 
tests are used in situations where the proportional hazards assumption does not apply, by 
allocating different weights to events according the events’ times.  
 
Linear-rank tests 
Apart from the log rank test, there exist other nonparametric tests, cumulatively 
named linear rank tests, which are generalized nonparametric methods for testing the null 
hypothesis of equal survival distribution among groups. An early example of such a test is 
the Gehan test (Magel, 1991; Shen & Le, 2000; Williamson, Lin, & Bush, 2002; 
Philonenko, Postovalov, & Kovalevskii, 2016). Gehan’s test is a generalization of the 
popular Wilcoxon-Mann-Whitney test for the two‐group comparison problem. Gehan’s 
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where 𝑋′' and 𝑌′( represent censored observations. 
Harrington (2005) describe the link between the log rank, Gehan and various other linear-



















If 𝑊 = 1, then the statistic is reduced to the original log rank statistic. On the other hand, 
if 𝑊 ≠ 1, we end up with various other tests.  For example, if W is the proportion of cases, 
then the statistic is reduced to the Gehan statistic. Since the proportion of cases of each 
group is used as weights, the Gehan statistic is slightly more powerful than the Log rank 
test under the nonproportionality assumption (Harrington, 2005). 
 
Buyse’s generalized Gehan test 
More recently, Buyse (2009), proposed a generalized Gehan test, which is based on 
the concept of the “net survival benefit”. Buyse’s idea is based on the fact that, if survival 
time between two groups is denoted by 𝑋and 𝑌, then there is a hierarchy of outcomes such 
that 𝑋 − 𝑌 > 𝜏	denotes a favorable outcome, while 𝑋 − 𝑌 < −𝜏 implies an unfavorable 
outcome and anything in between (i.e., |𝑋 − 𝑌| ≤ 𝜏) is inconclusive or neutral (Buyse, 
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2009). This idea can readily be extended to survival analysis in the sense of Gehan such 
that (Buyse, 2009) 
Pairwise comparison Pair is 
𝑋' − 𝑌( > 𝜏 
P𝑋' − 𝑌(P ≤ 𝜏 




𝑋'+ − 𝑌( > 𝜏 
P𝑋'+ − 𝑌(P ≤ 𝜏 




𝑋' − 𝑌(+ > 𝜏 
P𝑋' − 𝑌(+P ≤ 𝜏 




𝑋'+ − 𝑌(+ > 𝜏 
P𝑋'+ − 𝑌(+P ≤ 𝜏 





Table 1: Generalized pairwise comparison for a time-to-event variable (Buyse, 2010). 
where 𝑋' and 𝑌( are the observed failure times in the two groups and 𝑋'+ and 𝑌(+ are the 
respective censored cases.  Buyse’s generalized Gehan test is based on 𝜏 the net survival 
benefit. It expands the options for the null hypothesis in cases where survival advantages 
𝜏 > 0 may not be meaningful. It must be noted that Buyse’s test reduces to the usual Gehan 
test when 𝜏 = 0. 
 
  In this report the objective is to compare the statistical power of non-parametric 
procedures for testing the equality of two survival distributions when the proportionality 
assumption of the hazards is violated. The procedures used are the log rank and Buyse’s 




As the calculation of the variability of the distributions involved in the various tests 
considered here are complicated to derive, we will use simulation-based tests to determine 
critical regions and thresholds of rejection of the null hypothesis. Such randomization test 
can be used to test the null hypothesis 𝐻#: ∆= 𝜏, 𝜏 ≥ 0, and to calculate confidence 
intervals for the observed difference in the survival between two treatments ∆,-.. The 
randomization tests attempt to mimic (simulate) the assumed data generated mechanism 
under the null hypothesis. They generate repeated realizations of the results under the null 
hypothesis (say B). Operationally, this is done by keeping all individual times to event 
unchanged but permuting the individual treatment labels which are re-allocated at random 
(Basu, 1980). This is the reason that randomization tests are also called permutation tests. 




As an illustration of the above methods, we present a reanalysis of a clinical trial in 
oncology. The Gastrointestinal Tumor Study Group (1982) compared chemotherapy versus 
combined chemotherapy and radiation therapy in the treatment of locally unresectable 
gastric cancer. Survival times in days, for the 45 patients on each treatment were recorded. 
Considerations of delayed treatment effect were present in this study, suggesting that the 
survival benefit may not have been time-independent (i.e., constant and thus proportional 
between the two groups). We first performed a Kaplan-Meier analysis of their data.  Figure 
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1 presents the Kaplan-Meier plot that compares chemotherapy versus combined 
chemotherapy and radiation therapy in the treatment of locally unresectable gastric cancer. 
 
In the figure, the x axis represents the time (in days), while the y axis shows the 
survival probability.  The chemotherapy-only arm exhibits higher survival than 
chemotherapy plus radiation from the beginning till approximately 800 days. After that, 
the chemotherapy-plus-radiation arm tends to exhibit higher survival than chemotherapy 
until the end of follow-up. As can be observed from Figure 1, the estimated survival curves 
cross, which suggests that the hazards are not proportional.  
As usual, the hypotheses of interest are: 
 
Figure 1: Kaplan-Meier plot for the Gastrointestinal Tumor Study Group (1982) 
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H0 = chemotherapy only and chemotherapy plus radiation have the same survival 
distribution. 
H1= chemotherapy only and chemo plus radiation do not have the same survival 
distribution. 
The log-rank statistic for the data is 𝐾 = 0.2319 and the associated p-value = 
0.6301; since the p-value is greater than 0.05 we fail to reject the null hypothesis. From the 
Kaplan-Meier plot, we see that the survival function from the treatment groups cross which 
suggests a violation of the proportional hazard function, which in turn suggests that the 
power of the log-rank test to detect the differences (in survival) between the groups is 
reduced. This may be because of a delayed treatment effect or early toxicity in the 
chemotherapy-plus-radiation arm, as the Kaplan Meier curve for chemotherapy-only 
patients shows better survival in the earlier time points. 
An alternative test to this one is the Wilcoxon (Gehan) test. 
The Wilcoxon statistic is 𝐾/ = 3.9965 with p-value = 0.0456; since the P-value is 
less than 0.05 we reject the null hypothesis and conclude that there is evidence of an overall 
difference in survival between the two treatment groups. This conclusion is different from 
the one we made when we preformed the log-rank test. Because the Wilcoxon statistic puts 








Chapter Three: Results 
The results of the previous analysis are shown in Figure 2.  In this analysis we have 
turned the scale from days into months by dividing by 365.25 – average year length in days 
– and multiplying by 12 – number of months in a year. The brown line is the Generalized 
Gehan test statistic (Buyse, 2009) for 𝜏 equal to 0 and up to 120 months.  The green and 
the blue lines are the empirical upper and lower 95% confidence interval bound (i.e., the 
97.5th and 2.5th percentiles of the empirical distribution of the Generalized Gehan test based 
on 1,000 permutation tests as described in the Methods Section. (Simulated under no 
treatment effect.) The red line denotes the median (i.e., 50th percentile of the same empirical 
distribution). 
 
Figure 2: Generalized Wilcoxon Statistic for various months 
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At  𝛥 = 0, 𝑈(0) = 491,	The corresponding confidence interval for the data 
simulated with no treatment effect is (-127, 388). If we think of this confidence interval as 
representing the range of values that might be observed if there is no treatment effect, then 
the fact 491 is outside this range indicates that the chemotherapy only treatment increases 
survival probability for a benefit of zero months. This favorable effect was not maintained 
when the analysis was focused on long-term survival differences (e.g. 𝛥 =12 months).  One 
can observed from the Kaplan-Meier plots that the treatment survival lines cross at about 
two years this means that tests that weight time periods equally will not find any difference 
between the treatments. But tests that put more emphasis on the first month might show 
more value on the chemotherapy only treatment Recall that the log-rank test was not 
statistically significant for even Δ=0.  
In this study, 𝑈(12) = 219. The confidence interval assuming no treatment effect 
is ( -154, 61). So, the chemotherapy only treatment does not provide a treatment benefit 
longer than 12 months. The curve for the U statistic crosses the simulated median at about 
two years, this is the same points where the Kaplan-Meier cross. The radiation therapy does 
best at 54 months, even though it is not significant.  But the curve above seems to support 
the investigators’ assertion of a possible delayed treatment effect, which gives the early 
advantage to the chemotherapy-only treatment arm and later advantage to adding radiation.  
The power of the generalized Wilcoxon statistic compared favorably to the standard log-
rank test. In addition, the generalized Gehan test of Buyse (2009) suggests that the survival 





Chapter Four: Conclusions 
The net long-term survival benefit achieved via generalized Wilcoxon statistic is a 
measure of treatment effect that is meaningful whether or not hazards are proportional. The 
associated statistical test is more powerful than the standard log-rank test when a delayed 
treatment effect is anticipated.  This covers the case where the patient is unwilling to 
undergo treatment unless there is a long-term benefit, such as 12 months or more.  It also 
covers the case where the treatment, such as radiation therapy causes long term harm even 
though it provides short term survival benefits. Or radiation might be harmful in the short 
term but may keep the cancer from coming back in the long term.  These analysis methods 
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